Related Experiment Video
Updated: Sep 19, 2025
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Fibrinogen time course in acute ischemic stroke patients treated with intravenous thrombolysis with alteplase or
Aikaterini Theodorou1, Klearchos Psychogios2, Odysseas Kargiotis2
1Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece.
Introduction:
Limited data exist on intravenous thrombolysis (IVT) effect on fibrinogen depletion, and on possible associations between low fibrinogen levels and hemorrhagic complications, among acute ischemic stroke (AIS) patients.
Patients And Methods:
We conducted a prospective cohort study evaluating fibrinogen levels prior to IVT and at two prespecified timepoints following IVT end (2 and 24 h). Safety and efficacy outcomes were assessed. Fibrinogen depletion was defined as reduction < 200 mg/dl, or as reduction ⩾ 50% of baseline fibrinogen levels after 2 and 24 h from IVT. Furthermore, we conducted a systematic review and meta-analysis, comparing fibrinogen level changes from baseline to a timeframe of 2-12 h, and to 24 h post-IVT between patients receiving alteplase versus tenecteplase.
Results:
One hundred and sixteen AIS patients, treated with IVT (alteplase = 81, tenecteplase = 35) were included in this study. Alteplase was associated with higher rates of fibrinogen depletion, observed in 2 (38% vs 0%; p-value < 0.001) and 24 h (26% vs 0%; p-value: 0.002) post-IVT, compared to tenecteplase. Three symptomatic intracranial hemorrhages (sICH) and one major extracranial bleeding were observed in patients receiving alteplase (two out of four with fibrinogen depletion) and one sICH without associated fibrinogen depletion was documented in the tenecteplase subgroup. Major hemorrhagic complications were numerically higher in patients with fibrinogen depletion (6.5% vs 3.5%, p = 0.609). Fibrinogen depletion was documented in 50% of alteplase-treated patients complicated with sICH or major extracranial bleeding and in 0% of respective tenecteplase-treated patients. Two cohorts were included in the meta-analysis. Mean relative changes of fibrinogen levels from baseline to a timeframe of 2-12 h post-IVT (RoM: 9.84; 95% CI: 9.63-10.05) were significantly higher in patients receiving alteplase.
Discussion And Conclusions:
Fibrinogen depletion was observed only in AIS patients receiving alteplase and was associated with numerically higher rates of major hemorrhagic complications. These findings require independent confirmation in larger, international cohort studies.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:29Venous Thrombosis III: Interprofessional Care
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...